Gurgaon, Haryana, India, February 2025 – Winselow Tucker has been appointed as President and General Manager of Lilly India, bringing extensive leadership experience in global pharmaceutical commercialization, oncology, and market strategy. In his new role, Winselow will lead Lilly India’s strategic growth, innovation initiatives, and expansion of patient-centric healthcare solutions in the region. His appointment reflects Lilly’s commitment to strengthening its presence in India and advancing its portfolio of life-changing medicines.
Prior to joining Lilly India, Winselow Tucker was Senior Vice President and Chief Commercial Officer, Oncology at Loxo@Lilly, where he played a key role in commercializing cutting-edge oncology therapies and driving global market strategies. His leadership at Lilly Oncology focused on accelerating innovation, expanding market access, and delivering impactful treatment solutions.
Before his tenure at Lilly, he was Senior Vice President at Bristol Myers Squibb, where he led Intercontinental operations and U.S. Hematology, overseeing commercialization, market access, and pricing strategies for transformative hematology treatments. Previously, he was Corporate Vice President and General Manager, U.S. Hematology and Oncology at Celgene, where he spearheaded the launch of novel therapies, including CAR T-cell treatments to enhance patient outcomes.
Earlier in his career, Winselow held senior leadership roles at Novartis Oncology, including General Manager for Canada and Vice President of Global Product Strategy for breast cancer therapies. He also served as Vice President of Global Commercialization and Immuno-Oncology Strategy at Bristol Myers Squibb, driving immuno-oncology innovations and early oncology development. His pharmaceutical expertise spans commercial leadership, business strategy, and market access in global and regional roles, making him an asset in leading Lilly India’s future growth.
About Lilly India
Eli Lilly and Company (India) Pvt. Ltd., headquartered in Gurgaon, is a wholly owned subsidiary of Eli Lilly and Company, USA. Since its establishment in 1993, Lilly India has been at the forefront of offering advanced treatment options for chronic diseases, including diabetes, breast cancer, psoriasis, osteoporosis, lung cancer, and gastric cancer. Globally, Lilly is a leader in biopharmaceutical innovation, pioneering life-changing medicines that benefit over 51 million people worldwide. With a strong focus on diabetes, obesity, Alzheimer’s disease, immunology, and oncology, Lilly remains committed to expanding access to healthcare and driving medical breakthroughs.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
